newsfilter
← Latest News
Business Wire·

Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results

Multiple abstracts accepted for presentation at 2025 ASCO and AACR annual meetings underscore breadth of Bicycle® technology and potential of oncology pipeline Phase 1/2 Duravelo-3 trial for zelenectide pevedotin